Sangamo Therapeutics (SGMO) Competitors

Sangamo Therapeutics (NASDAQ:SGMO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Which has more volatility and risk, SGMO or LXRX?

Sangamo Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Is SGMO or LXRX more profitable?

Sangamo Therapeutics has a net margin of -77.48% compared to Lexicon Pharmaceuticals' net margin of -206.43%. Lexicon Pharmaceuticals' return on equity of -83.63% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-77.48%	-293.05%	-63.85%
Lexicon Pharmaceuticals	-206.43%	-83.63%	-42.22%

Do insiders & institutionals hold more shares of SGMO or LXRX?

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media prefer SGMO or LXRX?

In the previous week, Sangamo Therapeutics had 5 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 11 mentions for Sangamo Therapeutics and 6 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.27 beat Sangamo Therapeutics' score of 0.94 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sangamo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate SGMO or LXRX?

Sangamo Therapeutics currently has a consensus price target of $4.50, suggesting a potential upside of 675.86%. Lexicon Pharmaceuticals has a consensus price target of $3.23, suggesting a potential upside of 160.08%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Sangamo Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lexicon Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has stronger earnings and valuation, SGMO or LXRX?

Sangamo Therapeutics has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$57.80M	3.03	-$97.94M	-$0.29	-2.00
Lexicon Pharmaceuticals	$31.08M	14.50	-$200.40M	-$0.33	-3.76

Summary

Sangamo Therapeutics beats Lexicon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.